Eli Lilly and Company LLY

$1,347.11 -4.01 (-0.30%)

Valuation

Market cap
1,271,059,328,000
Revenue TTM
$65,179,000,000
Net income TTM
$20,640,000,000
P/E (trailing)
43.28
P/E (forward)
38.73
Profit margin
31.67%
Debt to equity
1.17

Trading

Volume
3,546,855
Avg volume
2,664,180
Day's range
$1,341.76 – $1,372.05
Shares out
940,745,000
Stochastic %K
4%
Beta
0.40
Analysts
Strong Buy
Price target
$1,519.18

Price

Company profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humu...

Show more

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
317 276 2000
Website
https://www.lilly.com
Address
Lilly Corporate Center, Indianapolis, United States

Latest news

Stocktwits

basedchad Nov 21, 3:35 PM 0 replies
MannyG_ Nov 21, 3:04 PM 0 replies
dewmoore Nov 21, 2:56 PM
$SLS yes if they announce pancreatic trials begin q1 that is what takes us to $35 or higher hell thats what $LLY paid for a damn phase 1 hematology company WTH ! the marketing team for $SLS sucks! amytime you go on FOX news first and NOT CNBC and bloomberg it says you have a bad pr team despite payimg all that damn money for them you got the cash now stop f@cking up the pr you can have the best drug in the world but with a horrible pr team we are toast !!!! no big bio company would allow you to go to jpm conference without a deal if you announce pancreatic or even ovarian phase 2 trial to kick off in q1 we hit $30 super easy which is our floor pre readout now LFG!
0 replies
Cpstrag Nov 21, 1:22 PM
$LLY plz split or buy RVMD thank you ! A peaceful grateful Thanksgiving folks !💋
0 replies
AllAboutTheBread Nov 21, 2:32 AM
$LLY dump this dog shit stock
0 replies
Biotechs2027 Nov 21, 1:02 AM
$CATX CATX, that makes Lilly a credible potential partner. Lilly already has access to Pb-212 through AdvanCell, so the reason to do a deal would be what CATX’s SSTR2-targeted NET drug adds to Lilly’s pipeline. $LLY
1 replies
WolverineVcapitalllc Nov 20, 11:55 PM
$ANT Tennessee in the plume diabolical um 😶 $LLY $SLS save me
1 replies
TradeWithInsight Nov 20, 10:49 PM
$SNDK led Sunday's watchlist this week: 825P under 848, the 804 target hit Monday and the 738 shelf broke after that 🎯 puts were up 92% by Tuesday. The rest: $LLY 1480C over 1450 triggered Monday, calls up 51% at the 1475 high, then stopped at 1437. $CRWD 210P under 219 triggered Monday and stopped at 222. $META 660C over 648 never triggered (high 640.70). 1 target, 2 stops, 1 no entry. Next list goes out Sunday. What was your best trade this week?
0 replies